Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Identification and targeting of metabolic dependencies in high-risk AML

FY 2021-22

Summary
Acute Myeloid Leukemia (AML) is a heterogenous disease, with a diversity of genetic subgroups and outcomes. Bleak outcomes are common for certain subtypes due to lack of response to therapy, high relapse rates, as well as a lack of targeted therapies. One such group are the Inv(3)/t(3;3) AMLs characterized by high levels of the transcriptional regulator MDS1-EVI1 Complex (MECOM). MECOM is highly expressed in healthy hematopoietic stem cells (HSCs) but is deregulated in AML. MECOM is also an independent negative prognostic factor for achieving complete remission and is associated with inferior overall survival. Currently, patient treatment protocols are very similar for all genetic risk groups of AML, and there is no targeted treatment for MECOM+ AMLs. Recently, modulation of energy metabolism, in particular oxidative phosphorylation (OXPHOS), has shown promise as a novel treatment since leukemic stem cells (LSCs) have a higher reliance on OXPHOS. The first aim of this proposal is to define the mitochondrial respiration capacity of MECOM low and MECOM high cell lines. The second aim of this proposal is to elucidate whether MECOM levels correlate with sensitivity to OXPHOS inhibitors in human AML cell lines. The third and final aim of this proposal is to perform a synergy drug screen with OXPHOS inhibitors and chemotherapeutics to determine the most effective drug combinations targeting MECOM expressing AML cells. Overall, targeting OXPHOS represents a therapeutic opportunity for MECOM expressing AML and has the potential to establish a targeted therapy and transform health care for this patient population.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
466895
Name
Partrick Owen W
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identification and targeting of metabolic dependencies in high-risk AML
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acute Myeloid Leukemia; Chemotherapy; Electron Transport Chain; Energy Metabolism Modulation; Inv(3)/T(3;3); Leukemic Stem Cells; Mecom; Mitochondria; Oxphos Inhibitors; Targeted Therapy
Abstract
Acute Myeloid Leukemia (AML) is a heterogenous disease, with a diversity of genetic subgroups and outcomes. Bleak outcomes are common for certain subtypes due to lack of response to therapy, high relapse rates, as well as a lack of targeted therapies. One such group are the Inv(3)/t(3;3) AMLs characterized by high levels of the transcriptional regulator MDS1-EVI1 Complex (MECOM). MECOM is highly expressed in healthy hematopoietic stem cells (HSCs) but is deregulated in AML. MECOM is also an independent negative prognostic factor for achieving complete remission and is associated with inferior overall survival. Currently, patient treatment protocols are very similar for all genetic risk groups of AML, and there is no targeted treatment for MECOM+ AMLs. Recently, modulation of energy metabolism, in particular oxidative phosphorylation (OXPHOS), has shown promise as a novel treatment since leukemic stem cells (LSCs) have a higher reliance on OXPHOS. The first aim of this proposal is to define the mitochondrial respiration capacity of MECOM low and MECOM high cell lines. The second aim of this proposal is to elucidate whether MECOM levels correlate with sensitivity to OXPHOS inhibitors in human AML cell lines. The third and final aim of this proposal is to perform a synergy drug screen with OXPHOS inhibitors and chemotherapeutics to determine the most effective drug combinations targeting MECOM expressing AML cells. Overall, targeting OXPHOS represents a therapeutic opportunity for MECOM expressing AML and has the potential to establish a targeted therapy and transform health care for this patient population.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Partrick, Owen W
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~